Drug Trial Radar · NCT05162755
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Oct 15, 2021
Primary completion
Feb 1, 2024
Study completion May 5, 2026
Sponsor
- Lead sponsor
- Institut de Recherches Internationales ServierAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ADIR, a Servier Group company
- First posted
- Dec 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor malignancies followed by an expansion phase of triple combinations. \*The study sponsor has made the decision not to move forward to the expansion part of the study due to strategic considerations, unrelated to any safety issues or concerns. The study will be stopped after completion of dose escalation parts 1a and 1b of the study.
Conditions
- Solid Tumor
Interventions
S095029Drug
S095029 will be administered via IV infusion every 2 weeks. Once the DLT evaluations period at the second dose level is completed and it is deemed as safe, the dose escalation part 1b will be initiated.
S95029 and Sym021Drug
Sym021 will be administered at a fixed dose of 200mg. S095029 will be administered via IV infusion every 2 weeks. Once the RP2D dose of S95029 in combination with Sym21 is defined, dose expansion will begin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AEs) (Dose escalation part)Time frame: Through study completion, up to 2 years
- Incidence of dose limiting toxicities (DLTs) (Dose escalation part)Time frame: At the end of Cycle 1 (each cycle is 28 days)
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
START Midwest
Grand Rapids, Michigan
Mary Crowley Cancer Research
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
The START Center for Cancer Care
San Antonio, Texas
Princess Margaret Cancer Centre
Toronto, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.